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Introduction
Cell-based gene therapy is a rapidly growing area of research. This approach offers several advantages over other types of viral and nonviral gene delivery systems currently being utilized to treat human diseases. Cells can be grown in vitro and genetically engineered to secrete high levels of a therapeutic protein. Long-term expression of biologically relevant proteins can be maintained, thus making successive injections and continual invasive procedures unnecessary. Safety concerns with the use of adenoviral vectors is a major consideration when designing gene therapy treatments of disease. By using cell-based gene therapy, this is not a critical issue, as cells can be carefully screened and characterized before injection.
Various cells have been reported as potential vehicles for use in gene therapy, but there have been many roadblocks in the way of utilizing their potential, including instability and lack of long-term viability. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] The ultimate cell to be used for cell-based gene therapy has the requirements of being easily cultured, easily transfected with genetic material, able to secrete high levels of an exogenous protein, able to be transplanted in vivo, nonmalignant, and no observed host-versus-graft effects.
Atherosclerotic cardiovascular disease is the leading cause of death in the Western world today. Various genetic and environmental factors have been implicated in the manifestation of atherosclerosis. 11 Among the genetic factors, lipoprotein abnormalities seem to play a key role in the pathogenesis of this disease. Apolipoprotein E (apoE) is one of the best characterized plasma apolipoproteins. [12] [13] [14] [15] ApoE is a glycoprotein with a molecular size of approximately 34 kDa. 16 The major site of synthesis of apoE in humans and normal mice is the liver although other tissues, such as the brain, spleen, adrenal gland, lung, testis, macrophages and ovary, are known to synthesize this protein. [17] [18] [19] [20] [21] In lipoprotein metabolism, apoE plays a major role in facilitating the cellular uptake of low density lipoproteins (VLDL) and chylomicron remnants by serving as a ligand on lipoprotein particles for the VLDL receptor and the putative remnant receptor. [22] [23] [24] [25] [26] [27] In humans, apoE is one of two known ligands for the low density lipoprotein (LDL) receptor. 28 Type III hyperlipoproteinemia and atherosclerotic coronary heart diseases have been found to be associated with genetic variation of apolipoprotein E resulting in defective receptor binding. 29 Normal inbred strains of mice do not develop atherosclerotic lesions spontaneously on a standard diet, although different strains of mice exhibit heritable differences in the levels of their circulating lipids. 30, 31 An apoEdeficient mouse model (apoE−/−) has been described by two groups of independent investigators. 32, 33 The apoEdeficient mice have been found to have five times normal plasma cholesterol levels. These mutant mice develop foam cell-rich depositions in their proximal aortas within 3 months, which progress to cause severe occlusion of the coronary arteries by age 7-8 months. This animal model yields a severe yet viable phenotype, which is ideal for studying the effect of new strategies on the development of atherosclerosis.
Recently, bone marrow transplantation was used to correct the apoE deficiency in apoE-deficient mice. 34, 35 ApoE expressing macrophages or blood cells appeared to correct the metabolic defect, and to inhibit the atherosclerotic symptoms in these animals. In an alternative gene therapy approach, apoE deficiency was successfully corrected utilizing recombinant adenovirus vectors expressing human apoE. 36 Systemic delivery of adenoviruses expressing the human apoE to mouse liver was achieved and resulted in normalized plasma apoE levels. Significant reduction of aortic atherosclerotic mean lesion area was obtained when compared with control apoEdeficient mice. These findings indicate the great potential of gene replacement. However, both of these strategies have limitations. Bone marrow transplantation and subsequent injection of transfected cells is labor intensive, requires histocompatibility matching, irradiation of the host, and has significant morbidity and mortality associated with the procedure. The use of adenoviruses to deliver genes is subject to all the safety concerns associated with adenoviral gene therapy. Furthermore, adenoviral vectors provide only a transient therapy and are immunogenic which hinders the success of later reinjections and long-term treatment. 37 An approach using a novel endothelial cell-based gene therapy for the expression of apoE in an atherosclerosis model is described in this study. An endothelial cell line derived from murine yolk sacs was stably transfected with a plasmid construct containing the human apoE gene and a high expressing apoE+ cell line was selected (Pro 175/apoE+). These engineered cells were injected into apoE-deficient mice as an in vivo mini-organ system. A decrease in cholesterol levels as well as in plaque formation was observed in treated animals for over 3 months. In addition, the stable yolk sac (YS) cell lines express classic endothelial markers, are stable, easily transfected with genetic material, express no detectable levels of MHC I under normal growth conditions, and have been maintained untransformed for over 50 passages in vitro. These results support the continued evaluation of these cells for long-term cell-based gene therapy.
Results
Characterization of YS endothelial cells Cells were isolated from the YS tissues of mice and cultured for a long period of time, some cultures having been expanded now for over 100 passages with no apparent change in morphology, growth characteristics, or endothelial cell surface marker phenotype. The YS cell clone Pro175 was found to be positive for the following endothelial markers: VCAM, flk-1, ACE, and acetylated LDL receptor (Table 1) . Pro 175 cells also formed tubelike structures when cultured on Matrigel (Collaborative Biomedical Products) (Figure 1 ), which is a characteristic of endothelial cells such as HUVECs (Clonetics). Interestingly, these cells do not express MHC I markers in vitro 
Treatment of atherosclerosis with genetically engineered YS cells expressing apoE protein
To study the ability of Pro175 cells to secrete biologically relevant proteins, these cells were transfected with a human apoE3 gene expression plasmid. After G418 selection, the level of apoE expression was measured in 30 clones by an apoE ELISA. The highest apoE expressing clone secreted 150 ng/24 h/10 6 cells and was used in the following animal experiments.
ApoE+/Pro175 cells were embedded in Matrigel and injected intradermally in the lower abdomen of apoEdeficient mice at age 6-8 weeks. Because the Matrigel solidifies at body temperature, the injected cells remained clustered and formed 'mini-organs' in the animals. The cholesterol levels in the negative control animals (five animals injected with untransfected Pro175 cells) and in the five apoE+/Pro175 animals were monitored bimonthly before and after the cell injection. A statistical analysis was performed on the data of the cholesterol levels from week 0 until week 16. Owing to the death of some of the animals on days 12,14 and 16, some groups do not contain the same amounts of animals per group throughout the study. The levels of cholesterol of the ApoE animals were statistically lower compared with the levels of their nontreated counterparts (P Ͻ 0.03). As is typical in this animal model, the cholesterol levels continued to rise in the control animals reaching an absolute level of 391 mg/dl which represents 231% of pre-injection levels 16 weeks after injection (Figure 2) . 33 In contrast, a decrease in cholesterol levels was observed in the animals having received the apoE secreting mini-organ as soon as 2 weeks after the injection and remained under the baseline level until week 16. After 3 months, the miniorgans were examined and found to be vascularized with no sign of tumorigenicity at the site of injection or elsewhere.
Qualitative analysis of plaque formation in the heart Consistent with the reported pathology in this model, untreated animals (five) developed severe aortic plaques (Figure 3c and d) . Large lesions were found throughout the aorta, some of which showed extensive calcification. In contrast, the experimental animals (five) receiving the apoE secreting mini-organs showed considerably less lesion and plaque formation (Figure 3a and b) .
Ex vivo mini-organ YS apoE expression
Despite a sensitive apoE ELISA method, no detectable levels of apoE were found in the serum of any of the experimental animals. Single cell cultures were established from several mini-organs and evaluated for the secretion of apoE. The ex vivo expression of apoE in the apoE+/Pro175 cells was even higher (up to 1000 versus 150 ng/24 h/10 6 cells) than seen in the primary cultures of these cells. This continued high expression of apoE cells after these cells have been removed from the animals indicates that the cells were functional in the animal and have probably enhanced their secretion capability. The lack of apoE-detection in the treated animal may be due to a rapid cycling due to the high levels of cholesterol. 
Discussion
The current study was undertaken to determine the efficacy of using a novel endothelial cell line (Pro175) isolated from the murine yolk sac as a potential candidate for cell-based gene therapy. There have been various cell types which have been studied for their potential usefulness in gene therapy, including epithelial cells, endothelial cells, skin fibroblasts and myoblasts, but each of these cell lines has had problems with viability, secretion, long-term culture or rejection. 1, 3, [7] [8] [9] [10] The use of endothelial YS cells in gene therapy offers several advantages over currently used systems. These cells have a long lifespan even after being grafted in animals, they retain their phenotype over an extended period of time, they are good secretors of exogenous foreign proteins, and they are not tumorigenic when grafted in immunocompromised animals. Furthermore, these YS endothelial cells form hollow capillary-like structures when incubated under the appropriate conditions. These endothelial tubes may anastomose with the host vascular system, leading to a more efficient delivery of proteins. Lastly, these cells do not spontaneously express MHC I antigens. Other studies utilizing murine YS cells have shown them not to be immunogenic in immunocompetent animals.
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Figure 3 Cardiac sections from control and experimental apoE-deficient animals. H&E staining of sections (a, b) from experimental animals receiving apoE secreting YS mini-organs and (c, d) from animals killed after 3 months receiving control YS mini-organs. Note severe lesion formation in the control aortic region indicated by arrows, whereas there is little plaque formation seen in the experimental apoE animal.
This immunological property may be an important feature, should these cells be used in allogeneic or xenogeneic settings. Future studies are planned to study these immunological properties of YS cells in appropriate model systems.
We have chosen the atherosclerosis disease model as a method in which to study the potential of our YS cells to secrete a biologically relevant protein, apoE3. In the present study, engineered YS endothelial cells were used to secrete apoE using a mini-organ strategy with the goal of averting atherosclerotic lesions in apoE-deficient mice. Several animal models have been proposed to study the mechanisms of atherosclerosis and to develop new treatments. Among these animal models, mice that lack the apoE3 gene are readily available. In this animal model, the phenotype features no detectable apoE3 secretion, high total serum cholesterol levels (five times normal levels), high VLDL and chylomicron levels, and severe aortic lesions which can be seen as early as 3 months of age.
The delivery of apoE by a variety of methods has been described. [34] [35] [36] [38] [39] [40] Although adenovirus-based gene transfer strategies are powerful, they raise major safety concerns when envisioned for treating long-term human diseases such as atherosclerosis. 37 Also, gene expression from these vectors is only transient and strong immunological responses increase the risk of further injections. Alternatively, bone marrow transplantation after irradiation has also been used for gene delivery of apoE, however, this method has high morbidity and mortality associated with it. 34, 35, 40 Transformed cell lines such as BHK expressing the apoE gene may be tumorigenic and fibroblastic lines such as NIH/3T3 cells may have only a limited life-span.
In the current study, Pro175 cells were engineered with a plasmid bearing the human apoE3 cDNA driven by the CMV promoter. High levels of apoE expression were obtained in vitro before grafting these cells. Similarly, the cells were still secreting high levels of apoE after having been in the animals for 12 weeks. The in vivo tests showed that animals containing mini-organs secreting apoE were found to have significantly lower cholesterol levels than control animals. Even though there was a dramatic effect observed, apoE secretion did not reach detectable levels in the serum of the experimental animals. One possible explanation for this is that the apoE protein was being quickly linked to the lipids, taken up by the cells and transported to tissues, thereby having a low serum concentration in these animals. This explanation is corroborated by the fact that Bellosta et al 35 found only 3-8% of normal apoE levels after irradiation and injection of apoE+ macrophages. Despite the lack of detectable levels of apoE in the ApoE+/Pro 175 animals, apoE was being secreted by the cells as indicated by the in vitro culture of the cells. In addition, it is difficult to explain the effects on cholesterol levels and on lesion area other than by a significant apoE secretion. Experiments are being planned to investigate tissues such as the liver to determine if there are detectable levels of apoE sequestered in the individual tissues in the animals.
In accordance with the apoE in vitro assays and the cholesterol in vivo assays, a significant reduction in the aortic lesion areas was observed in the experimental animals when compared with the control animals 3 months after the mini-organ implantation. Contrasting with the experimental animals, the control apoE-deficient animals showed severe plaque formation containing calcified areas as well as infiltration of a large population of foam cells.
In conclusion, the use of endothelial YS cells in gene therapy offers several advantages over currently used systems which are being utilized to deliver missing proteins. Bone marrow transplantation results in significant morbidity and mortality associated with this procedure and adenovirus-and retrovirus-based gene transfer strategies raise major safety issues in the treatment of human diseases. Alternatively, transformed cell lines may be tumorigenic and fibroblastic lines may have only a limited life-span. Thus, a well established YS endothelial cell line such as Pro175 may be a good platform for long-term in vivo protein production. Indeed, these cells have a long life-span even after being grafted, they retain their phenotype over an extended period of time, they are good secretors of exogenous foreign proteins, and they are not transformed cells. Furthermore, these YS endothelial cells may develop vascular structures that may anastomose with the host vascular system, leading to a more efficient delivery of proteins. This first study using the mini-organ strategy and YS-derived endothelial cells for the treatment of atherosclerosis in apoE-deficient mice has shown efficacy and the potential of the system. Cellbased therapy may have numerous applications in diseases other than cardiovascular diseases such as diabetes and endocrinopathies. Future studies are necessary to evaluate the transplantation issues, the mode of implantation and/or the encapsulation devices.
Materials and methods
Endothelial yolk sac cell lines Murine yolk sacs were isolated from day 8-9 pregnant females (C57BL/6J) and dispersed by gentle aspiration in 0.025% trypsin. They were then placed on 0.1% gelatincoated dishes in culture medium containing alpha MEM (Gibco/BRL, Gaithersburg, MD, USA), 18% fetal bovine serum (FBS, Hyclone), 10% conditioned medium containing 40 ng/ml LIF, 70 m MTG (Sigma), and 50 g/ml gentamicin (Gibco/BRL). These cells are mildly adherent and require treatment with mild trypsinization (0.25%) or PBS/EDTA (1 mm) for passage or for single cell preparations. The stable YS cell line used in this study is named Pro175. For some experiments, Pro 175 c-ells were placed on dishes pre-coated with Matrigel (Collaborative Biomedical Products) at 2 × 10 5 cells/35 mm. The cells were cultured under standard conditions at 37°C, 5% CO 2 , and their morphology and amount of endothelial cell network formation was photographed.
PCR analysis
Total cellular RNA was isolated and extracted using Ultraspec-II RNA Isolation System (Biotecx Laboratories, Houston, TX, USA). cDNA was generated using RNA PCR core reagents and a 9600 gene amp thermocycler (Perkin Elmer). All reactions were standardized based on the relative expression of the ␤-actin gene. The cDNA primers for ␤-actin were 5Ј-GTGACGAGGCCCAGAGCA AGA-3Ј (forward) and 5Ј-AGGGGCCGGACTCATC GTACTC-3Ј (reverse). The primers for flk-1 were 5Ј-AGCTGTCGCTCTGTGGTTCT-3Ј (forward) and 5Ј-TG GGGAGAGTAAAGCCTATC-3Ј (reverse). The ACE primers were 5Ј-TGC ACTGGTGGTATCTTCGAACCA-3Ј (forward) and 5Ј-CATACTCTTCCACGAACCTGTCAG-3Ј (reverse). Each reaction was amplified using the following PCR conditions: 94°C (30 s), 53°C (30 s) and 72°C (30 s), the total number of cycles was 40. Ethidium bromide staining following agarose gel electrophoresis confirmed the expected 934 bp product for ␤-actin, the 551 bp product for flk-1, and a 500 bp product for ace.
Flow cytometry LDL receptor analysis
The rapid uptake of a fluorogenic derivative of acetylated low density lipoprotein (dilAcLDL) (Biomedical Technologies, Palatine, IL, USA) was measured by incubating cells for 4 h at 37°C with alpha-MEM containing 10 g/ml of dilAcLDL. After washing three times, the cells were fixed in 3% paraformaldehyde and visualized under a fluorescent microscope for characteristic punctate fluorescence of receptor-mediated update of dilAcLDL. To identify cell surface markers, the cells were removed from tissue culture flasks by PBS/EDTA treatment. Cells (10 6 ) were then stained for 40 min in PBS containing 0.1% BSA and 0.1% NaN 3 with 1 g/100 l of anti-mouse CD105 (VCAM-1), Mac-1, F4/80, MHC I (H2K b ), MHC II (I-A h ), or rat IgG2A isotype control (Pharmingen). After washing, cells were incubated with 1 g/ml anti-rat IgG FITC-labeled secondary antibody (Southern Biotechnology Associates, Birmingham, AL, USA) and fixed with 1% freshly prepared paraformaldehyde in PBS. The yolk sac cells were quantified by flow cytometry analysis (EPICS XL; Coulter). Parallel experiments were run on unfixed cells which, following staining, were also characterized by flow cytometric analysis.
MHC induction with ␥-interferon
Yolk sac cells were plated (800/cm 2 ) and cultured in primary endothelial medium with 400 U/ml ␥-IFN (Genzyme, Cambridge, MA, USA) for 96 h. 41 The primary endothelial medium consists of the following components: DMEM (Gibco/BRL), 10% FBS (Hyclone), 1% BME vitamins (Gibco/BRL), 25 g/ml heparin (Sigma), 50 g/ml ECGS (Collaborative Biomedical Products), 20% EOMA-conditioned medium, and 50 g/ml gentamicin. The cells were harvested, blocked with 1 g/ml anti-Fc receptor antibody (Pharmingen) and incubated with 1 g/ml FITC-conjugated anti-MHC I (H2K 
Plasmid construction and transfection procedures
The human apoE3 cDNA fragment was obtained by an EcoRI/HindIII digestion from the pHE53 plasmid. 43 The isolated 1200 bp fragment was cloned into the pcDNA3 expression plasmid (Invitrogen, Carlsbad, CA, USA). For cell transfection, plasmid DNA was obtained using Qiagen columns (Santa Clarita, CA, USA). Following an ethanol precipitation and wash step, plasmid DNA was resuspended in sterile endotoxin free water at a concentration of 500 ng/l.
For transfection and selection, Pro175 YS cells (2.5 × 10 5 cells/35 mm dish) in 2.5 ml YS complete medium (alpha-MEM, 18% FBS, 40 ng/ml of LIF, 70 m MTG, 50 g/ml gentamicin). The LIF was supplied in the form of a tissue culture supernatant from a recombinant LIF producing cell line. After an overnight incubation, the cells were washed twice with OPTI-MEM (Gibco/BRL) and incubated for 6 h at 37°C with a mixture of Lipofectin (Gibco/BRL) and 2 g of apoE expression plasmid DNA. 43 Fresh YS complete medium was added and after 48 h cells were subcultured in selection medium containing 500 g/ml of active G418 (Gibco/BRL). Stable clonal cell populations were isolated after 2-3 weeks in selection medium. The supernatants from each clone were assayed for apoE protein by ELISA and individual clones expressing high levels of apoE protein (Pro175/apoE+) were selected for further investigation. Animals C57BL/6J apoE-deficient mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA). The animals were maintained on a normal chow diet, and housed in autoclaved filter top cages with autoclaved water and kept on a 12 h light-dark cycle. Blood was obtained after overnight fasting by retro-orbital puncture under anesthesia. Serum was isolated by centrifuging blood samples at 13 000 g for 10 min and stored at −20°C.
Mini-organ technology
To induce localized engraftment, Pro175/apoE+ YS cells (10 7 /ml) were embedded in Matrigel (Collaborative Biomedical Products) supplemented with 40 ng/ml VEGF and 10 ng/ml bFGF. The cell preparations were carried out at 4°C to ensure that the Matrigel component remained in the liquid state. 44 Each animal was given an intradermal injection of 0.5 ml Matrigel cell solution in the lower abdomen region. This 'mini-organ' was allowed to develop and serum cholesterol levels were determined on a bi-weekly basis throughout the experimental period.
Lipid and apoE assays
The serum cholesterol levels were determined by using a Diagnostics Cholesterol Reagent (Sigma). Briefly, 5 l of serum was incubated with 200 l of cholesterol reagent for 30 min at room temperature. 45 The samples were then assayed for total serum cholesterol by comparing the absorbance at 490 nm with cholesterol standards. A repeated measures analysis of variance was performed on the cholesterol levels using the GLM procedure in the SAS statistical package.
The tissue culture supernatant and serum apoE levels were determined by an apoE ELISA methodology. To increase sensitivity and reproducibility, protein extraction of the serum samples was performed using 15% butanol, 85% di-isopropyl ether. 46 The concentration of apoE was then determined by incubating the samples for 2 h (37°C) on an ELISA plate coated with (1 g per well) affinity purified goat anti-human apoE (Biodesign International, Kennebunk, ME, USA). The plate was then washed and incubated for 2 h (37°C) with (2 g per well) biotin-labeled goat anti-human apoE (Biodesign International). After incubation, 0.5 g/ml alkaline phosphatase streptavidin (Kirkegaard and Parry Laboratories) was added and subsequently developed with phosphatase substrate (Kirkegaard and Parry Laboratories, Gaithersburg, MD, USA). The apoE in the experimental samples was measured by comparison with a standard curve of human apoE protein (Chemicon, Temecula, CA, USA), which was spiked into control pre-bleed serum. The positive controls in this assay were normal serum from normal animals, as well as normal serum from apoE-deficient animals spiked with corresponding levels of apoE protein for use in the standard curve. The detection range of the standard curve is 0.1 ng/ml to 100 ng/ml.
Histology
The hearts were dissected from the experimental and control animals after 3 months, and placed in a 10% formalin fixative for 24 h. These samples were embedded in paraffin and sectioned according to the protocol proposed by Paigen et al. 47 Several sections from each heart were stained with a standard hematoxyline/eosin procedure and then analyzed for plaque formation in the aortic region. Five slides from each control and experimental group were evaluated. Photographs were taken from each representative region in control and treated animals and qualitatively compared.
